The Influence of Testosterone on Experimental Pain Perception

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

EARLY_PHASE1

Total Enrollment

20 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-10-01

Study Completion Date

2018-07-17

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This trial examined how the administration of exogenous testosterone would influence pain tolerance and other endogenous steroids (i.e. estradiol and progesterone).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Effects of Testosterone Replacement on Pain Sensitivity and Pain Perception

NCT00351819

Pain Hypogonadism

COMPLETED PHASE2

Testosterone and Pain Sensitivity

NCT01689896

Low Testosterone Hypogonadism Pain

WITHDRAWN PHASE4

Pain Alleviation With Testosterone in Opioid-Induced Hypogonadism

NCT04798469

Opioid Use Pain Hypogonadism, Male

RECRUITING PHASE2

Study on the Effects of Exogenous Testosterone on Threat Perception and Behavioral Avoidance

NCT01408498

Testosterone's Effects on Threat Perception/Response

COMPLETED NA

Effects of Osteoarthritis Pain, Morphine, and Placebo on Neuroendocrine Function in Men

NCT00088296

Osteoarthritis

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Acute Pain

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

OTHER

Blinding Strategy

DOUBLE

Participants Investigators

The investigational drug pharmacy providing the sublingual testosterone masked the drugs. Neither the participants nor the investigators knew who was receiving testosterone.

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Testosterone

Sublingual testosterone

Group Type EXPERIMENTAL

Testosterone

Intervention Type DRUG

Sublingual testosterone was administered to participants. Participants would self-administer the testosterone to themselves.

Placebo Syrup

Intervention Type OTHER

Oil-based sublingual product.

Placebo

Group Type PLACEBO_COMPARATOR

Testosterone

Intervention Type DRUG

Sublingual testosterone was administered to participants. Participants would self-administer the testosterone to themselves.

Placebo Syrup

Intervention Type OTHER

Oil-based sublingual product.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Testosterone

Sublingual testosterone was administered to participants. Participants would self-administer the testosterone to themselves.

Intervention Type DRUG

Placebo Syrup

Oil-based sublingual product.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Healthy college-aged females that are over the age of 18 and younger than 25 will be used for this study.

Exclusion Criteria

* The following criteria will exclude a participant from the study:
* Anyone that has a tree nut allergy.
* Women that are pregnant or may feel that they may be pregnant or breast-feeding.
* Anyone taking supplements that may influence their testosterone level.
* Anyone taking any kind of steroid that may increase their testosterone level.
* Anyone that smokes tobacco or uses smokeless tobacco.
* Anyone that reports any condition associated with nerve damage.
* Anyone that is using hormonal contraceptive.
* Anyone who was sick or unwell at the time of screening.
* Each participant completed a Testosterone Pre-Screen form. This form asked each participant individually whether they are taking any drugs or have any conditions that might be exacerbated by testosterone. This form was completed before they signed the consent form and each time they arrived in the lab for an experimental session.

Minimum Eligible Age

18 Years

Maximum Eligible Age

25 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

Yes